Bank of New York Mellon’s NovoCure NVCR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $4.63M | Buy |
305,516
+24,045
| +9% | +$364K | ﹤0.01% | 2484 |
|
|
2026
Q1 | $3.07M | Sell |
281,471
-17,057
| -6% | -$213K | ﹤0.01% | 2588 |
|
|
2025
Q4 | $3.86M | Sell |
298,528
-31,566
| -10% | -$405K | ﹤0.01% | 2463 |
|
|
2025
Q3 | $4.26M | Buy |
330,094
+7,390
| +2% | +$98.7K | ﹤0.01% | 2415 |
|
|
2025
Q2 | $5.74M | Sell |
322,704
-1,888
| -0.6% | -$32.9K | ﹤0.01% | 2190 |
|
|
2025
Q1 | $5.78M | Buy |
324,592
+2,062
| +0.6% | +$46.8K | ﹤0.01% | 2151 |
|
|
2024
Q4 | $9.61M | Buy |
322,530
+10,071
| +3% | +$213K | ﹤0.01% | 1944 |
|
|
2024
Q3 | $4.88M | Sell |
312,459
-107,501
| -26% | -$1.95M | ﹤0.01% | 2296 |
|
|
2024
Q2 | $7.19M | Buy |
419,960
+152,185
| +57% | +$2.68M | ﹤0.01% | 2140 |
|
|
2024
Q1 | $4.19M | Sell |
267,775
-46,138
| -15% | -$679K | ﹤0.01% | 2406 |
|
|
2023
Q4 | $4.69M | Sell |
313,913
-48,568
| -13% | -$650K | ﹤0.01% | 2397 |
|
|
2023
Q3 | $5.85M | Sell |
362,481
-77,981
| -18% | -$2.25M | ﹤0.01% | 2231 |
|
|
2023
Q2 | $18.3M | Sell |
440,462
-5,829
| -1% | -$362K | ﹤0.01% | 1603 |
|
|
2023
Q1 | $26.8M | Sell |
446,291
-8,622
| -2% | -$689K | 0.01% | 1388 |
|
|
2022
Q4 | $33.4M | Sell |
454,913
-14,833
| -3% | -$1.12M | 0.01% | 1248 |
|
|
2022
Q3 | $35.7M | Buy |
469,746
+77,899
| +20% | +$6.08M | 0.01% | 1162 |
|
|
2022
Q2 | $27.2M | Buy |
391,847
+63,603
| +19% | +$4.79M | 0.01% | 1362 |
|
|
2022
Q1 | $27.2M | Sell |
328,244
-3,860
| -1% | -$284K | 0.01% | 1475 |
|
|
2021
Q4 | $24.9M | Buy |
332,104
+4,741
| +1% | +$476K | ﹤0.01% | 1590 |
|
|
2021
Q3 | $38M | Sell |
327,363
-822
| -0.3% | -$124K | 0.01% | 1319 |
|
|
2021
Q2 | $72.8M | Sell |
328,185
-34,068
| -9% | -$6.63M | 0.01% | 896 |
|
|
2021
Q1 | $47.9M | Sell |
362,253
-34,326
| -9% | -$5.43M | 0.01% | 1136 |
|
|
2020
Q4 | $68.6M | Buy |
396,579
+63,811
| +19% | +$8.73M | 0.01% | 847 |
|
|
2020
Q3 | $37M | Buy |
332,768
+34,875
| +12% | +$2.79M | 0.01% | 1087 |
|
|
2020
Q2 | $17.7M | Sell |
297,893
-42,707
| -13% | -$2.81M | ﹤0.01% | 1521 |
|
|
2020
Q1 | $22.9M | Sell |
340,600
-14,740
| -4% | -$1.16M | 0.01% | 1213 |
|
|
2019
Q4 | $29.9M | Buy |
355,340
+1,609
| +0.5% | +$130K | 0.01% | 1314 |
|
|
2019
Q3 | $26.5M | Sell |
353,731
-24,625
| -7% | -$1.97M | 0.01% | 1357 |
|
|
2019
Q2 | $23.9M | Buy |
378,356
+33,018
| +10% | +$1.67M | 0.01% | 1454 |
|
|
2019
Q1 | $16.6M | Buy |
345,338
+13,989
| +4% | +$673K | ﹤0.01% | 1665 |
|
|
2018
Q4 | $11.1M | Sell |
331,349
-55,909
| -14% | -$2.04M | ﹤0.01% | 1834 |
|
|
2018
Q3 | $20.3M | Buy |
387,258
+21,335
| +6% | +$849K | 0.01% | 1612 |
|
|
2018
Q2 | $11.5M | Buy |
365,923
+166,834
| +84% | +$4.64M | ﹤0.01% | 1948 |
|
|
2018
Q1 | $4.34M | Sell |
199,089
-51,618
| -21% | -$1.11M | ﹤0.01% | 2425 |
|
|
2017
Q4 | $5.07M | Buy |
250,707
+47,676
| +23% | +$918K | ﹤0.01% | 2357 |
|
|
2017
Q3 | $4.03M | Buy |
203,031
+2,724
| +1% | +$53.5K | ﹤0.01% | 2449 |
|
|
2017
Q2 | $3.46M | Buy |
200,307
+26,784
| +15% | +$346K | ﹤0.01% | 2517 |
|
|
2017
Q1 | $1.41M | Buy |
173,523
+2,480
| +1% | +$17.9K | ﹤0.01% | 3060 |
|
|
2016
Q4 | $1.34M | Buy |
171,043
+17,736
| +12% | +$143K | ﹤0.01% | 3095 |
|
|
2016
Q3 | $1.31M | Buy |
153,307
+16,216
| +12% | +$148K | ﹤0.01% | 3030 |
|
|
2016
Q2 | $1.6M | Buy |
137,091
+114,190
| +499% | +$1.43M | ﹤0.01% | 2850 |
|
|
2016
Q1 | $332K | Buy |
22,901
+7,196
| +46% | +$103K | ﹤0.01% | 3604 |
|
|
2015
Q4 | $351K | Buy |
+15,705
| New | +$375K | ﹤0.01% | 3660 |
|
Other funds holding NVCR
CWG
PAM
BC
TCA
Bank of New York Mellon's NVCR Position: Q2 2026 in Review
Bank of New York Mellon increased its NovoCure (NVCR) stake by 8.5% in Q2 2026, buying an estimated $364K and bringing the position to 305,516 shares worth $4.63M. The position accounts for ﹤0.01% of the portfolio, ranked #2484.
Bank of New York Mellon first reported a position in NVCR in Q4 2015 and has held it in 43 quarters since. The position peaked at $72.8M in Q2 2021. 84 funds tracked by Wall St. Rank hold NVCR as of Q2 2026.
- Bank of New York Mellon held 305,516 shares of NovoCure worth $4.63M as of Q2 2026.
- Bank of New York Mellon bought 24,045 NovoCure shares in Q2 2026, an estimated $364K.
- NovoCure made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #2484 holding.
- Bank of New York Mellon first reported a position in NovoCure in Q4 2015 and has held it in 43 quarters since.
- Bank of New York Mellon's NovoCure position peaked at $72.8M in Q2 2021.
- 84 funds tracked by Wall St. Rank held NovoCure as of Q2 2026.
Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.